Panelists:
Fyodor Urnov, PhD
Scientific Director
Innovative Genomics Institute
Tom Foti
VP & General Manager
Protein Business Unit
Aldevron
Tim Morris
Manager Upstream Development
Aldevron
- Time:
In this live webinar, one of the pioneers of human genome editing—Dr. Fyodor Urnov—will lay out the urgent challenge facing the clinical genome editing community in terms of expanding the public health impact of CRISPR-Cas. A formidable financial, logistical, and regulatory hurdle in all genetic therapies is attaining scalable clinic-grade manufacture of the experimental therapeutic. The current costs, timelines, and requirements in that space make the vast majority of genetic disease intractable in a practical sense.
Dr. Urnov will discuss the unique nature of CRISPR-Cas as a platform technology that brings the promise of leveraging nonclinical and manufacturing information from one disease indication to another, potentially without repeating redundant, costly, and time-consuming nonclinical studies. The non-viral delivery of CRISPR-Cas, including as a Cas9 ribonucleoprotein (RNP), is a strong case study in this regard, where key aspects of the manufacturing framework could be leveraged between disease indications. Dr. Urnov will assess the latest progress in clinical genome editing and discuss how further progress could be enabled by creative academia-industry partnerships to develop and reduce to real-world-practice manufacturing innovation in the “CRISPR-Cas as a therapeutic platform” space.
Following this live presentation, Dr. Urnov took audience questions moderated by Aldevron leaders Tom Foti and Tim Morris.
Produced with support from:
